ArticleJapanese journal of clinical oncology2022

Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan.

Haruko Sugamori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.